Free Trial
NASDAQ:PDEX

Pro-Dex (PDEX) Stock Price, News & Analysis

Pro-Dex logo
$64.77 -2.73 (-4.04%)
Closing price 05/29/2026 04:00 PM Eastern
Extended Trading
$64.21 -0.56 (-0.86%)
As of 05/29/2026 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Pro-Dex Stock (NASDAQ:PDEX)

Advanced

Key Stats

Today's Range
$64.77
$68.39
50-Day Range
$46.54
$67.50
52-Week Range
$23.47
$68.39
Volume
41,023 shs
Average Volume
33,065 shs
Market Capitalization
$206.62 million
P/E Ratio
17.89
Dividend Yield
N/A
Price Target
$70.00
Consensus Rating
Hold

Company Overview

Pro-Dex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

PDEX MarketRank™: 

Pro-Dex scored higher than 46% of companies evaluated by MarketBeat, and ranked 635th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pro-Dex has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Pro-Dex is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Pro-Dex has only been the subject of 3 research reports in the past 90 days.

  • Read more about Pro-Dex's stock forecast and price target.
  • Earnings Growth

    Earnings for Pro-Dex are expected to decrease by -12.03% in the coming year, from $3.16 to $2.78 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pro-Dex is 17.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.96.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pro-Dex is 17.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.59.

  • Price to Book Value per Share Ratio

    Pro-Dex has a P/B Ratio of 5.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Pro-Dex's valuation and earnings.
  • Percentage of Shares Shorted

    11.06% of the float of Pro-Dex has been sold short.
  • Short Interest Ratio / Days to Cover

    Pro-Dex has a short interest ratio ("days to cover") of 6.69.
  • Change versus previous month

    Short interest in Pro-Dex has recently decreased by 19.13%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pro-Dex does not currently pay a dividend.

  • Dividend Growth

    Pro-Dex does not have a long track record of dividend growth.

  • News Sentiment

    Pro-Dex has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Pro-Dex this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for PDEX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pro-Dex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $626,242.00 in company stock.

  • Percentage Held by Insiders

    45.90% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    15.28% of the stock of Pro-Dex is held by institutions.

  • Read more about Pro-Dex's insider trading history.
Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PDEX Stock News Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

PDEX Stock Analysis - Frequently Asked Questions

Pro-Dex's stock was trading at $38.48 at the start of the year. Since then, PDEX stock has increased by 68.3% and is now trading at $64.77.

Pro-Dex, Inc. (NASDAQ:PDEX) announced its quarterly earnings data on Thursday, April, 30th. The medical instruments supplier reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.58. The medical instruments supplier earned $19.95 million during the quarter, compared to analysts' expectations of $17.90 million. Pro-Dex had a trailing twelve-month return on equity of 22.78% and a net margin of 16.08%.

Top institutional shareholders of Pro-Dex include Punch & Associates Investment Management Inc. (1.94%), Dimensional Fund Advisors LP (1.78%), Bank of New York Mellon Corp (0.34%) and Corsair Capital Management L.P. (0.34%). Insiders that own company stock include Kirk Richard Lee Van Jr, Alisha Charlton and Angelita Rebamontan Domingo.
View institutional ownership trends
.

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL).

Company Calendar

Last Earnings
4/30/2026
Today
5/31/2026
Fiscal Year End
6/30/2026
Next Earnings (Estimated)
7/08/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED/DENTAL - SUPP
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PDEX
CIK
788920
Employees
140
Year Founded
1975

Price Target and Rating

High Price Target
$70.00
Low Price Target
$70.00
Potential Upside/Downside
+8.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.62
Trailing P/E Ratio
17.89
Forward P/E Ratio
20.50
P/E Growth
N/A
Net Income
$8.98 million
Net Margins
16.08%
Pretax Margin
21.56%
Return on Equity
22.78%
Return on Assets
14.30%

Debt

Debt-to-Equity Ratio
0.32
Current Ratio
3.67
Quick Ratio
2.14

Sales & Book Value

Annual Sales
$66.59 million
Price / Sales
3.10
Cash Flow
$3.14 per share
Price / Cash Flow
20.66
Book Value
$11.23 per share
Price / Book
5.77

Miscellaneous

Outstanding Shares
3,190,000
Free Float
1,727,000
Market Cap
$206.62 million
Optionable
Not Optionable
Beta
-0.02

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:PDEX) was last updated on 5/31/2026 by MarketBeat.com Staff.
From Our Partners